Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Oncol. Nov 24, 2022; 13(11): 896-906
Published online Nov 24, 2022. doi: 10.5306/wjco.v13.i11.896
Table 3 Pathological characteristics of the tumors

Elective
Urgency
P value
T0.278c
Tis2 (1.6%)0
T16 (4.9%)0
T216 (13.0%)6 (9.1%)
T388 (71.5%)54 (81.8%)
T411 (8.9%)6 (9.1%)
N0.943a
N076 (61.8%)42 (63.6%)
N132 (26.0%)17 (25.8%)
N215 (12.2%)7 (10.6%)
Staging0.199c
02 (1.6%)0
I20 (16.3%)5 (7.6%)
II54 (43.9%)37 (56.1%)
III47 (38.2%)24 (36.4%)
Differentiation grade0.938c
Well7 (6.0%)3 (5.0%)
Moderate101 (87.1%)52 (86.7%)
Poor8 (6.9%)5 (8.3%)
Compromised lymph nodes rated8.1% ± 16.77.9% ± 17.10.785e
Angiolymphatic invasion44 (36.4%)21 (31.8%)0.533a
Perineural invasion19 (16.4%)7 (11.1%)0.339a
ALI + PNI16 (13.0%)5 (7.6%)0.257a